JDM  Vol.4 No.2 , May 2014
Effects of AGE Inhibition with Aminoguanidine in a Diabetic db/db Mouse Wound Model
Abstract: Advanced glycation end products (AGEs) react non-enzymatically with tissue proteins to form irreversible structures involved in atherosclerosis, nephropathy, retinopathy, neuropathy, and wound healing. Studies on AGE-inhibitors have demonstrated possible prevention of diabetes complications. The present open label study was conducted on aminoguanidine (AGu), an inhibitor of AGE-formation, to examine potential effects on wound healing in diabetes type 2-like db/db mice during 5 - 6 weeks. The animals were divided into 4 groups: AGu from the day of wounding (day 0) topically and/or systemically in drinking water (1 g/L; group 1, n = 13); AGu 1 g/L in drinking water from 7 weeks prior to day 0 (group 2, n = 21); AGu 5 g/L in drinking water from 9 - 11 weeks prior to day 0 (group 3, n = 6); placebo controls (group 4, n = 8). Results: Glycated hemoglobin (A1C) was significantly lower in group 3 compared to the other groups (P < 0.05). Percentage change in A1C and body weight from baseline to the end of the experiment were both related to the AGu doses (1 or 5 g/L; A1C-change, P = 0.01; weight-change, P = 0.04, both for linear trend across groups 4, 2, and 3, respectively). Even so, percentage wound closure was not improved in the AGu-treated groups compared to controls (P ≥ 0.8).
Cite this paper: Berdal, M. and Jenssen, T. (2014) Effects of AGE Inhibition with Aminoguanidine in a Diabetic db/db Mouse Wound Model. Journal of Diabetes Mellitus, 4, 107-114. doi: 10.4236/jdm.2014.42017.

[1]   Nagai, R., Murray, D.B., Metz, T.O. and Baynes, J.W. (2012) Chelation: A Fundamental Mechanism of Action ofAGE Inhibitors, AGE Breakers, and Other Inhibitors of Diabetes Complications. Diabetes, 61, 549-559.

[2]   Aso, Y., Inukai, T., Tayama, K. and Takemura, Y. (2000) Serum Concentrations of Advanced Glycation Endproducts Are Associated with the Development of Atherosclerosis as Well as Diabetic Microangiopathy in Patients with Type 2 Diabetes. Acta Diabetologica, 37, 87-92.

[3]   Makita, Z., Radoff, S., Rayfield, E.J., Yang, Z., Skolnik, E., Delaney, V., Friedman, E.A., Cerami, A. and Vlassara, H. (1991) Advanced Glycosylation End Products in Patients with Diabetic Nephropathy. The New England Journal of Medicine, 325, 836-842.

[4]   Sebag, J., Buckingham, B., Charles, M.A. and Reiser, K. (1992) Biochemical Abnormalities in Vitreous of Humans with Proliferative Diabetic Retinopathy. Archives of Ophthalmology, 110, 1472-1476.

[5]   Sugimoto, K., Nishizawa, Y., Horiuchi, S. and Yagihashi, S. (1997) Localization in Human Diabetic Peripheral Nerve of N(epsilon)-Carboxymethyllysine-Protein Adducts, an Advanced Glycation Endproduct. Diabetologia, 40, 1380-1387.

[6]   Loughlin, D.T. and Artlett, C.M. (2009) 3-Deoxyglucosone-Collagen Alters Human Dermal Fibroblast Migration and Adhesion: Implications for Impaired Wound Healing in Patients with Diabetes. Wound Repair and Regeneration, 17, 739-749.

[7]   Goova, M.T., Li, J., Kislinger, T., Qu, W., Lu, Y., Bucciarelli, L.G., Nowygrod, S., Wolf, B.M., Caliste, X., Yan, S.F., Stern, D.M. and Schmidt, A.M. (2001) Blockade of Receptor for Advanced Glycation End-Products Restores Effective Wound Healing in Diabetic Mice. The American Journal of Pathology, 159, 513-525.

[8]   Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P. and Cerami, A. (1986) Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking. Science, 232, 1629-1632.

[9]   Bolton, W.K., Cattran, D. C., Williams, M.E., Adler, S.G., Appel, G.B., Cartwright, K., Foiles, P.G., Freedman, B.I., Raskin, P., Ratner, R.E., Spinowitz, B.S., Whittier, F.C. and Wuerth, J.P. (2004) Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy. American Journal of Nephrology, 24, 32-40.

[10]   Ascher, E., Gade, P.V., Hingorani, A., Puthukkeril, S., Kallakuri, S., Scheinman, M. and Jacob, T. (2001) Thiamine Reverses Hyperglycemia-Induced Dysfunction in Cultured Endothelial Cells. Surgery, 130, 851-858.

[11]   Kelso, B.G., Brower, J.B., Targovnik, J.H. and Caplan, M.R. (2011) Pyridoxine Restores Endothelial Cell Function in High Glucose. Metabolic Syndrome and Related Disorders, 9, 63-68.

[12]   Gadau, S., Emanueli, C., Van Linthout S., Graiani, G., Todaro, M., Meloni, M., Campesi, I., Invernici, G., Spillmann, F., Ward, K. and Madeddu, P. (2006) Benfotiamine Accelerates the Healing of Ischaemic Diabetic Limbs in Mice through Protein Kinase B/Akt-Mediated Potentiation of Angiogenesis and Inhibition of Apoptosis. Diabetologia, 49, 405-420.

[13]   Flyvbjerg, A., Denner, L., Schrijvers, B.F., Tilton, R.G., Mogensen, T.H., Paludan, S.R. and Rasch, R. (2004) Long-Term Renal Effects of a Neutralizing RAGE Antibody in Obese Type 2 Diabetic Mice. Diabetes, 53, 166-172.

[14]   Teixeira, A.S., Caliari, M.V., Rocha, O.A., Machado, R.D. and Andrade, S.P. (1999) Aminoguanidine Prevents Impaired Healing and Deficient Angiogenesis in Diabetic Rats. Inflammation, 23, 569-581.

[15]   Ozturk, A., Firat, C., Parlakpinar, H., Bay-Karabulut, A., Kirimlioglu, H. and Gurlek, A. (2012) Beneficial Effects of Aminoguanidine on Skin Flap Survival in Diabetic Rats. Experimental Diabetes Research, 2012, Article ID: 721256.

[16]   Coleman, D.L. and Hummel, K.P. (1967) Studies with the Mutation, Diabetes, in the Mouse. Diabetologia, 3, 238-248.

[17]   Tesch, G.H. and Lim, A.K. (2011) Recent Insights into Diabetic Renal Injury from the db/db Mouse Model of Type 2 Diabetic Nephropathy. American Journal of Physiology—Renal Physiology, 300, F301-F310.

[18]   Lee, G.H., Proenca, R., Montez, J.M., Carroll, K.M., Darvishzadeh, J.G., Lee, J.I. and Friedman, J.M. (1996) Abnormal Splicing of the Leptin Receptor in Diabetic Mice. Nature, 379, 632-635.

[19]   Berdal, M., Appelbom, H.I., Eikrem, J. H., Lund, A., Zykova, S., Busund, L.T., Seljelid, R. and Jenssen, T. (2007) Aminated ?-1,3-D-Glucan Improves Wound Healing in Diabetic db/db Mice. Wound Repair and Regeneration, 15, 825-832.

[20]   Schaffer, M.R., Tantry, U., Thornton, F.J. and Barbul, A. (1999) Inhibition of Nitric Oxide Synthesis in Wounds: Pharmacology and Effect on Accumulation of Collagen in Wounds in Mice. European Journal of Surgery, 165, 262-267.

[21]   Greenhalgh, D.G., Sprugel, K.H., Murray, M.J. and Ross, R. (1990) PDGF and FGF Stimulate Wound Healing in the Genetically Diabetic Mouse. American Journal of Pathology, 136, 1235-1246.

[22]   Fleming, T.H., Theilen, T.M., Masania, J., Wunderle, M., Karimi, J., Vittas, S., Bernauer, R., Bierhaus, A., Rabbani, N., Thornalley, P.J., Kroll, J., Tyedmers, J., Nawrotzki, R., Herzig, S., Brownlee, M. and Nawroth, P.P. (2013) Aging-Dependent Reduction in Glyoxalase 1 Delays Wound Healing. Gerontology, 59, 427-437.

[23]   Berdal, M., Appelbom, H.I., Eikrem, J.H., Lund, A., Busund, L. T., Hanes, R., Seljelid, R. and Jenssen, T. (2011) Aminated β-1,3-D-Glucan Has a Dose-Dependent Effect on Wound Healing in Diabetic db/db Mice. Wound Repair and Regeneration, 19, 579-587. 00715.x

[24]   Berdal, M. and Jenssen, T. (2013) No Association between Glycemia and Wound Healing in an Experimental db/db Mouse Model. ISRN Endocrinology, 2013, 1-6.

[25]   Witte, M.B., Kiyama, T. and Barbul, A. (2002) Nitric Oxide Enhances Experimental Wound Healing in Diabetes. British Journal of Surgery, 89, 1594-1601. 02263.x

[26]   Makita, Z., Vlassara, H., Rayfield, E., Cartwright, K., Friedman, E., Rodby, R., Cerami, A. and Bucala, R. (1992) Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science, 258, 651-653.

[27]   Arakawa, K., Ishihara, T., Oku, A., Nawano, M., Ueta, K., Kitamura, K., Matsumoto, M. and Saito, A. (2001) Improved Diabetic Syndrome in C57BL/KsJ-db/db Mice by Oral Administration of the Na(+)-Glucose Cotransporter Inhibitor T-1095. British Journal of Pharmacology, 132, 578-586.

[28]   Piercy, V., Toseland, C.D. and Turner, N.C. (1998) Potential Benefit of Inhibitors of Advanced Glycation End Products in the Progression of Type II Diabetes: A Study with Aminoguanidine in C57/BLKsJ Diabetic Mice. Metabolism, 47, 1477-1480.